Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
43 hedge funds and large institutions have $27.8M invested in Argos Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 1 closing their positions.
2,200% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 1
533% more call options, than puts
Call options by funds: $443K | Put options by funds: $70K
105% more funds holding
Funds holding: 21 → 43 (+22)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
8% more capital invested
Capital invested by funds: $25.7M → $27.8M (+$2.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.69M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$917K |
| 3 |
State Street
Boston,
Massachusetts
|
+$808K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$700K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$395K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$178K |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$126K |
| 3 |
KeyBank National Association
Cleveland,
Ohio
|
-$74.6K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$72K |
| 5 |
WSA
Wall Street Associates
Lajolla,
California
|
-$62.1K |
ARGS Hedge Fund Activity: Q2 2016 in Review
43 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q2 2016, worth a combined $27.8M — up 8% from $25.7M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ARGS positions and 1 closed out — a net gain of 22 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $1.69M. The largest seller was Sanders Morris Harris, cutting an estimated $178K.
- 43 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q2 2016, up from 21 in Q1 2016.
- Funds reported $27.8M of Argos Therapeutics, Inc. stock for Q2 2016, up 8% quarter-over-quarter.
- 23 funds opened new Argos Therapeutics, Inc. positions in Q2 2016 and 1 closed out, a net change of +22 holders.
- The largest Argos Therapeutics, Inc. buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $1.69M added.
- The largest Argos Therapeutics, Inc. seller in Q2 2016 was Sanders Morris Harris, an estimated $178K sold.
Based on aggregated 13F filings for Q2 2016.